India Pharmaceuticals Industry Strategic Research Report 2026-2031

Publication ID:

NAV0826020

Publication Date:

August 26, 2026

Pages:

264

Countries:

India

$3,500.00

Buying Frequently for your Organization?

Click here to know more about our subscription packages.

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

The India Pharmaceuticals Market (IPM) is estimated at USD 27.8 billion in 2025 (base year), forecast to reach USD 50.0 billion by 2031, at a CAGR of approximately 8.4% across the 2025–2031 forecast period. Real historical data spans 2022–2024 (USD 20.8 billion in 2022), anchored to IQVIA India MIDAS and AIOCD-AWACS retail audit data, not estimated backward from a single base year.

This report independently verifies all 17 profiled companies' financial figures directly against their own official investor relations disclosures and annual reports, following a rigorous data refresh completed in August 2026 that identified and corrected several real discrepancies between commonly-cited estimates and companies' actual reported results.

The GLP-1 sub-segment within Anti-Diabetic therapy is the fastest-growing category in the entire IPM, and this report provides full reconciliation between India-specific IPM-tracked GLP-1 revenue and the broader Global GLP-1 Drug Market report's India country-line figures, since the two measure different channel scopes.

Scope of India Pharmaceuticals Industry Strategic Research Report

This report provides forecast data by value (USD Billion) for the India Pharmaceuticals Market (IPM), with 2025 as the base year, real historical data from 2022, and forecasting to 2031.
This report provides segment by type (Cardiovascular & Antihypertensive, Anti-Diabetic, Anti-infectives, Gastrointestinal, Vitamins, Minerals & Supplements, Respiratory, CNS / Neurology, Oncology (Prescription), Dermatology, Gynaecology, Other Therapeutic Areas) forecast data by value.
This report provides application/channel segments (Retail Pharmacy (Trade generics + Branded), Hospital / Institutional, Jan Aushadhi (Generic public stores), E-Pharmacy (1mg, Apollo, PharmEasy), Diagnostics-linked dispensing, Veterinary (pharma segment)) forecast data by value.
This report provides region-wise (West India, North India, South India, East India, Central India) forecast data by value.
This report also provides full state-wise forecast data across all five regions.
This report identifies key growth drivers and inhibitors affecting the India Pharmaceuticals Market.
This report provides company profiles including Company Overview, Key Products & Segments, Financial Performance, Business Strategy, and SWOT Analysis for 264-page-detailed, officially-verified companies.
This report provides Porter's Five Forces, PESTLE, and SWOT analysis for the India Pharmaceuticals Market.
This report identifies key future trends in the India Pharmaceuticals Market, including the GLP-1 biosimilar revolution and Ayushman Bharat-driven demand expansion.

Segment by Type in India Pharmaceuticals Industry Strategic Research Report

Cardiovascular & Antihypertensive
Anti-Diabetic
Anti-infectives
Gastrointestinal
Vitamins, Minerals & Supplements
Respiratory
CNS / Neurology
Oncology (Prescription)
Dermatology
Gynaecology
Other Therapeutic Areas

Segment by Application in India Pharmaceuticals Industry Strategic Research Report

Retail Pharmacy (Trade generics + Branded)
Hospital / Institutional
Jan Aushadhi (Generic public stores)
E-Pharmacy (1mg, Apollo, PharmEasy)
Diagnostics-linked dispensing
Veterinary (pharma segment)

Segment by Region in India Pharmaceuticals Industry Strategic Research Report

West India
- Maharashtra
- Gujarat
- Goa
North India
- Delhi NCR
- Uttar Pradesh
- Punjab
- Haryana
- Rajasthan
South India
- Tamil Nadu
- Karnataka
- Telangana
- Andhra Pradesh
- Kerala
East India
- West Bengal
- Odisha
- Bihar
- Jharkhand
- North-East India
Central India
- Madhya Pradesh
- Chhattisgarh

Who can use the India Pharmaceuticals Industry Strategic Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the India Pharmaceuticals Market. Some of the intended users for this report are:

C-level executives and Company Directors in pharmaceutical and healthcare companies
Industry consultants and Management consultants
Marketing professionals and Business development professionals
Investment managers, Financial professionals, and Venture Capitalists
Bank Managers, M&A Managers, and Auditors
Payers, Healthcare Policy Analysts, and Market Access professionals
Portfolio Managers and Equity Research Analysts covering Indian pharmaceuticals
Anyone operating in the India pharmaceutical value chain, from R&D through retail distribution

Table of Contents

Executive Summary
1. 1.1 India Pharmaceuticals Market (IPM) — Strategic Research Report 2026–2031
2. 1.2 Preamble and Market Definition
3. 1.3 Market Sizing and Growth Trajectory
4. 1.4 Key Structural Demand Drivers
5. 1.5 Therapy Area Performance: Differentiated Growth Across Categories
6. 1.6 GLP-1 Drug Market: India's Highest-Growth Emerging Segment
7. 1.7 Channel Transformation: E-Pharmacy and Institutional Disruption
8. 1.8 Competitive Landscape: Fragmented Market with Entrenched Leaders
9. 1.9 Branded Generic Market Structure: Evolution Without Disruption
10. 1.10 Key Findings Summary
11. 1.11 Report Scope and Data Integrity
Industry Overview & Forecast
1. 2.1 The India Pharmaceuticals Market: Structural Growth at Scale
2. 2.2 Market Size Trajectory and Annual Growth Dynamics
3. 2.3 Therapy Area Composition and Growth Differentials
4. 2.3.1 Cardiovascular and Antihypertensive: The Anchor Segment
5. 2.3.2 Anti-Diabetic: India's Fastest Major Therapy Category
6. 2.3.3 Anti-Infectives: The Maturing Pillar
7. 2.3.4 Oncology: The Premium Growth Driver
8. 2.3.5 Other Significant Therapy Areas
9. 2.4 Distribution Channel Evolution
10. 2.4.1 Retail Pharmacy: The Dominant but Slowly Declining Pillar
11. 2.4.2 Hospital and Institutional: Government Demand Pull Accelerating
12. 2.4.3 Jan Aushadhi: The Generic Access Wildcard
13. 2.4.4 E-Pharmacy: The Digital Disruption Channel
14. 2.5 Regional Demand Architecture
15. 2.6 Market Concentration and Competitive Structure
16. 2.7 Structural Inhibitors and Risk Factors
17. 2.8 Forecast Summary and Strategic Implications
Market Segmentation by Type
1. 3.1 Overview
2. 3.2 Cardiovascular and Antihypertensive
3. 3.3 Anti-Diabetic
4. 3.4 Anti-Infectives
5. 3.5 Gastrointestinal
6. 3.6 Vitamins, Minerals, and Supplements
7. 3.7 Respiratory
8. 3.8 CNS and Neurology
9. 3.9 Oncology: The Premium Growth Engine of the IPM
10. 3.10 Dermatology and Gynaecology
11. 3.11 Other Therapeutic Areas
12. 3.12 Segment Size Hierarchy and Growth Rate Ranking
Market Segmentation by Application
1. 4.1 Overview and Segmentation Framework
2. 4.2 Retail Pharmacy
3. 4.2.1 Scale, Structure, and Historical Trajectory
4. 4.2.2 Sub-channel Decomposition
5. 4.2.3 Competitive Dynamics in Retail Pharmacy
6. India Pharmaceuticals Industry Strategic Research Report 2026-2031
7. 4.3 Hospital and Institutional Channel
8. 4.3.1 Market Size and Structural Composition
9. 4.3.2 Private Hospital Sub-channel
10. 4.3.3 Government Institutional Sub-channel (Ayushman Bharat / PMJAY)
11. 4.3.4 ESI/CGHS Sub-channel
12. 4.4 Jan Aushadhi — Generic Public Stores
13. 4.4.1 Market Trajectory and Policy Momentum
14. 4.4.2 Competitive Implications for Branded Generics
15. 4.5 E-Pharmacy
16. 4.5.1 Rapid Formalisation of a High-Growth Channel
17. 4.5.2 Structural Drivers of E-Pharmacy Adoption
18. 4.5.3 Regulatory Environment for E-Pharmacy
19. 4.5.4 Competitive Landscape in E-Pharmacy
20. 4.6 Diagnostics-Linked Dispensing
21. 4.6.1 An Emerging Adjacency
22. 4.7 Veterinary Pharmaceuticals
23. 4.7.1 A Modest but Stable Segment
24. 4.8 Cross-Channel Analysis and Strategic Implications
25. 4.8.1 Channel Mix Evolution
26. 4.8.2 Implications for Manufacturer Strategy
27. 4.8.3 Policy Risk Concentration
28. 4.9 Summary Outlook by Application Segment
Regional Market Forecast
1. 5.1 West India
2. 5.2 North India
3. 5.3 South India
4. 5.4 East India
5. 5.5 Central India
Country-Level Market Forecast
1. 6.1 West India
2. 6.1.1 Maharashtra
3. 6.1.2 Gujarat
4. 6.1.3 Goa
5. 6.2 North India
6. 6.2.1 Delhi NCR
7. 6.2.2 Uttar Pradesh
8. 6.2.3 Punjab
9. 6.2.4 Haryana
10. 6.2.5 Rajasthan
11. 6.3 South India
12. 6.3.1 Tamil Nadu
13. 6.3.2 Karnataka
14. 6.3.3 Telangana
15. 6.3.4 Andhra Pradesh
16. 6.3.5 Kerala
17. 6.4 East India
18. 6.4.1 West Bengal
19. 6.4.2 Odisha
20. 6.4.3 Bihar
21. 6.4.4 Jharkhand
22. 6.5 Central India
23. 6.5.1 Madhya Pradesh
24. 6.5.2 Chhattisgarh
Growth Drivers & Inhibitors
1. 7.1 Overview
2. 7.2 Growth Drivers
3. 7.2.1 The Non-Communicable Disease Epidemic — Structural Demand Engine
4. 7.2.2 GLP-1 Receptor Agonist Market — High-Velocity Emerging Segment
5. 7.2.3 Ayushman Bharat & Government Health Coverage Expansion
6. 7.2.4 E-Pharmacy Channel Transformation
7. 7.2.5 Oncology Premiumisation & Specialty Drug Growth
8. 7.2.6 Production Linked Incentive (PLI) Scheme — Supply-Side Capacity Catalyst
9. 7.3 Growth Inhibitors
10. 7.3.1 NPPA Drug Price Control & NLEM Inclusion Risk
11. 7.3.2 Jan Aushadhi & Trade Generic Penetration
12. 7.3.3 Fragmented Market Structure & Pricing Competition
13. 7.3.4 Regulatory & Compliance Complexity — US FDA Warning Letters Affecting R&D Allocation
14. 7.3.5 INR/USD Depreciation — Revenue Translation & API Import Cost Pressure
15. 7.3.6 Post-COVID Anti-Infective Volume Normalisation
16. 7.4 Driver-Inhibitor Balance Assessment
Key Company Profiles
1. 8.1 Sun Pharmaceutical
2. 8.1.1 Company Overview
3. 8.1.2 Key Products & Segments
4. 8.1.3 Financial Performance (2023–2025)
5. 8.1.4 Business Strategy
6. 8.1.5 SWOT Analysis
7. 8.1.6 Strategic Implications (2025–2031)
8. 8.2 Cipla
9. 8.2.1 Company Overview
10. 8.2.2 Key Products & Segments
11. 8.2.3 Financial Performance (2023–2025)
12. 8.2.4 Business Strategy
13. 8.2.5 SWOT Analysis
14. India Pharmaceuticals Industry Strategic Research Report 2026-2031
15. 8.2.6 Strategic Implications (2025–2031)
16. 8.3 Alkem Laboratories
17. 8.3.1 Company Overview
18. 8.3.2 Key Products & Segments
19. 8.3.3 Financial Performance (2023–2025)
20. 8.3.4 Business Strategy
21. 8.3.5 SWOT Analysis
22. 8.3.6 Strategic Implications (2025–2031)
23. 8.4 Mankind Pharma
24. 8.4.1 Company Overview
25. 8.4.2 Key Products & Segments
26. 8.4.3 Financial Performance (2023–2025)
27. 8.4.4 Business Strategy
28. 8.4.5 SWOT Analysis
29. 8.4.6 Strategic Implications (2025–2031)
30. 8.5 Lupin
31. 8.5.1 Company Overview
32. 8.5.2 Key Products & Segments
33. 8.5.3 Financial Performance (2023–2025)
34. 8.5.4 Business Strategy
35. 8.5.5 SWOT Analysis
36. 8.5.6 Strategic Implications (2025–2031)
37. 8.6 Torrent Pharma
38. 8.6.1 Company Overview
39. 8.6.2 Key Products & Segments
40. 8.6.3 Financial Performance (2023–2025)
41. 8.6.4 Business Strategy
42. 8.6.5 SWOT Analysis
43. 8.6.6 Strategic Implications (2025–2031)
44. 8.7 Zydus Lifesciences
45. 8.7.1 Company Overview
46. 8.7.2 Key Products & Segments
47. 8.7.3 Financial Performance (2023–2025)
48. 8.7.4 Business Strategy
49. 8.7.5 SWOT Analysis
50. 8.7.6 Strategic Implications (2025–2031)
51. 8.8 Dr. Reddy's Labs
52. 8.8.1 Company Overview
53. 8.8.2 Key Products & Segments
54. 8.8.3 Financial Performance (2023–2025)
55. 8.8.4 Business Strategy
56. 8.8.5 SWOT Analysis
57. 8.8.6 Strategic Implications (2025–2031)
58. 8.9 Ipca Laboratories
59. 8.9.1 Company Overview
60. 8.9.2 Key Products & Segments
61. 8.9.3 Financial Performance (2023–2025)
62. 8.9.4 Business Strategy
63. 8.9.5 SWOT Analysis
64. 8.9.6 Strategic Implications (2025–2031)
65. 8.10 Abbott India
66. 8.10.1 Company Overview
67. 8.10.2 Key Products & Segments
68. 8.10.3 Financial Performance (2023–2025)
69. 8.10.4 Business Strategy
70. 8.10.5 SWOT Analysis
71. India Pharmaceuticals Industry Strategic Research Report 2026-2031
72. 8.10.6 Strategic Implications (2025–2031)
73. 8.11 Pfizer India
74. 8.11.1 Company Overview
75. 8.11.2 Key Products & Segments
76. 8.11.3 Financial Performance (2023–2025)
77. 8.11.4 Business Strategy
78. 8.11.5 SWOT Analysis
79. 8.11.6 Strategic Implications (2025–2031)
80. 8.12 Ajanta Pharma
81. 8.12.1 Company Overview
82. 8.12.2 Key Products & Segments
83. 8.12.3 Financial Performance (2023–2025)
84. 8.12.4 Business Strategy
85. 8.12.5 SWOT Analysis
86. 8.12.6 Strategic Implications (2025–2031)
87. 8.13 Aurobindo (India formulations)
88. 8.13.1 Company Overview
89. 8.13.2 Key Products & Segments
90. 8.13.3 Financial Performance (2023–2025)
91. 8.13.4 Business Strategy
92. 8.13.5 SWOT Analysis
93. 8.13.6 Strategic Implications (2025–2031)
94. 8.14 Natco Pharma
95. 8.14.1 Company Overview
96. 8.14.2 Key Products & Segments
97. 8.14.3 Financial Performance (2023–2025)
98. 8.14.4 Business Strategy
99. 8.14.5 SWOT Analysis
100. 8.14.6 Strategic Implications (2025–2031)
101. 8.15 Biocon (Branded formulations)
102. 8.15.1 Company Overview
103. 8.15.2 Key Products & Segments
104. 8.15.3 Financial Performance (2023–2025)
105. 8.15.4 Business Strategy
106. 8.15.5 SWOT Analysis
107. 8.15.6 Strategic Implications (2025–2031)
108. 8.16 IOLAB / Piramal (Consumer health)
109. 8.16.1 Company Overview
110. 8.16.2 Key Products & Segments
111. 8.16.3 Financial Performance (2023–2025)
112. 8.16.4 Business Strategy
113. 8.16.5 SWOT Analysis
114. 8.16.6 Strategic Implications (2025–2031)
115. 8.17 Sanofi India
116. 8.17.1 Company Overview
117. 8.17.2 Key Products & Segments
118. 8.17.3 Financial Performance (2023–2025)
119. 8.17.4 Business Strategy
120. 8.17.5 SWOT Analysis
121. 8.17.6 Strategic Implications (2025–2031)
Competitive Landscape
1. 9.1 Competitive Landscape Overview
2. 9.2 Competitive Intensity Assessment
3. 9.2.1 Player Tier Structure and Revenue Ranges
4. 9.2.2 Capacity vs. Demand Dynamics
5. India Pharmaceuticals Industry Strategic Research Report 2026-2031
6. 9.2.3 Pricing Environment
7. 9.2.4 Barriers to Entry and Exit
8. 9.3 Key Player Strategies & Positioning
9. 9.3.1 Strategic Group Mapping
10. 9.3.2 Differentiation Strategies by Major Player
11. 9.3.3 Geographic Strongholds
12. 9.3.4 M&A and Partnership Activity (2022–Present)
13. 9.3.5 R&D and Technology Investment Trends
14. 9.4 Competitive Dynamics & Strategic Outlook
15. 9.4.1 Emerging Competitive Threats
16. 9.4.2 Consolidation vs. Fragmentation Outlook
17. 9.4.3 Competitive Response Matrix
18. 9.4.4 Strategic Recommendations for 2025–2031
Porter's Five Forces Analysis
1. 10.1 Threat of New Entrants
2. 10.2 Bargaining Power of Buyers
3. 10.3 Bargaining Power of Suppliers
4. 10.4 Threat of Substitutes
5. 10.5 Competitive Rivalry
PESTLE Analysis
1. 11.1 Political
2. 11.1.1 Government Healthcare Ambition as a Structural Demand Driver
3. 11.1.2 Production-Linked Incentive (PLI) Scheme — Industrial Policy Backbone
4. 11.1.3 Drug Price Control and NPPA Regulation
5. 11.1.4 Geopolitical Positioning — India as Global Pharma Supplier
6. 11.2 Economic
7. 11.2.1 Macro Growth and Pharmaceutical Spending Correlation
8. 11.2.2 Currency Dynamics and USD Revenue Translation Risk
9. 11.2.3 Out-of-Pocket Healthcare Expenditure — Market Structure Determinant
10. 11.2.4 Fragmented Market Structure and Consolidation Economics
11. 11.3 Social
12. 11.3.1 The NCD Epidemic — Structural Demand Architecture
13. 11.3.2 Demographic Dividend and Urban Migration
14. 11.3.3 Healthcare Awareness and Therapy Compliance Evolution
15. 11.3.4 Cultural Dynamics — The Branded Generic Prescription Culture
16. 11.4 Technological
17. 11.4.1 Biosimilar Innovation — Market Transformation at Scale
18. 11.4.2 E-Pharmacy and Digital Distribution Transformation
19. 11.4.3 Manufacturing Technology — Quality Assurance and Regulatory Compliance
20. 11.4.4 Digital Health Integration — AI and Diagnostics
21. 11.5 Legal
22. 11.5.1 Drug Price Control — NLEM and Beyond
23. 11.5.2 Intellectual Property — The Patent Cliff and Compulsory Licensing
24. 11.5.3 Regulatory Framework — CDSCO and Drug Approval Pathways
25. 11.6 Environmental
26. 11.6.1 Climate Risk and Agricultural API Feedstocks
27. 11.6.2 Environmental Compliance — Manufacturing Discharge and Sustainability
28. 11.6.3 ESG as a Competitive Differentiator
29. 11.6.4 Sustainability in Packaging and Logistics
30. 11.7 PESTLE Summary Assessment
SWOT Analysis
1. 12.1 Overview and Analytical Framework
2. 12.2 Strengths
3. 12.2.1 Structural Demand Engine: World's Largest NCD Epidemic
4. 12.2.2 Branded Generic Model Creates Durable Competitive Moats
5. 12.2.3 Deep Manufacturing Capability and API Self-Sufficiency Trajectory
6. 12.2.4 Biosimilar Leadership Unlocking New Market
7. 12.3 Weaknesses
8. 12.3.1 Pricing Controls and DPCO Compression on Branded Margins
9. 12.3.2 Intense Market Fragmentation Limiting Competitive Rationalization
10. 12.3.3 Skewed Urban-Rural Distribution Infrastructure
11. 12.3.4 Dependence on API Imports — Residual China Risk
12. 12.4 Opportunities
13. 12.4.1 GLP-1 Biosimilar Market — The Fastest-Growing IPM Sub-Segment
14. 12.4.2 Ayushman Bharat and Health Insurance Penetration Expanding the Addressable Market
15. 12.4.3 Oncology Premium Growth — Specialty Drug Premiumisation
16. 12.4.4 E-Pharmacy Channel Transformation — New Distribution Economics
17. 12.5 Threats
18. 12.5.1 Escalating Generic Substitution — Jan Aushadhi and Trade Generic Pressure
19. 12.5.2 Regulatory Price Intervention Risk — NPPA and DPCO Expansion
20. 12.5.3 Multinational Competition in High-Value Therapeutic Categories
21. 12.5.4 Geopolitical and Supply Chain Disruption Risk
22. 12.6 SWOT Summary Matrix
Future Trends & Outlook
1. 13.1 Overview
2. 13.2 Trend One: The GLP-1 Biosimilar Revolution and the Obesity-Diabetes Nexus
3. 13.3 Trend Two: NCD Epidemic Acceleration Driving Chronic Therapy Growth
4. 13.4 Trend Three: Ayushman Bharat and Government-Led Demand Expansion
5. 13.5 Trend Four: E-Pharmacy Channel Disruption and Digital Distribution Transformation
6. 13.6 Trend Five: Biosimilar Premiumisation and the Specialty Biologics Market
7. 13.7 Trend Six: Competitive Consolidation and M&A-Driven Market Structure Evolution
8. 13.8 Outlook Summary: 2026–2031 Key Projections

List of Exhibits

Exhibit 1: 3.1: Forecast of Cardiovascular & Antihypertensive (in USD Bn)
Exhibit 2: 3.2: Forecast of Antihypertensive (in USD Bn)
Exhibit 3: 3.3: Forecast of Cardiac (Statins, Anti-anginal) (in USD Bn)
Exhibit 4: 3.4: Forecast of Anticoagulants & Others (in USD Bn)
Exhibit 5: 3.5: Forecast of Anti-Diabetic (in USD Bn)
Exhibit 6: 3.6: Forecast of Oral Anti-diabetics (Metformin, DPP4) (in USD Bn)
Exhibit 7: 3.7: Forecast of GLP-1 (Ozempic, Mounjaro, Biosim) [IPM-tracked only] (in USD Bn)
Exhibit 8: 3.8: Forecast of Insulin analogues (in USD Bn)
Exhibit 9: 3.9: Forecast of Anti-infectives (in USD Bn)
Exhibit 10: 3.10: Forecast of Antibiotics (Cephalosporins, etc.) (in USD Bn)
Exhibit 11: 3.11: Forecast of Antifungals & Antivirals (in USD Bn)
Exhibit 12: 3.12: Forecast of Gastrointestinal (in USD Bn)
Exhibit 13: 3.13: Forecast of Vitamins, Minerals & Supplements (in USD Bn)
Exhibit 14: 3.14: Forecast of Respiratory (in USD Bn)
Exhibit 15: 3.15: Forecast of CNS / Neurology (in USD Bn)
Exhibit 16: 3.16: Forecast of Oncology (Prescription) (in USD Bn)
Exhibit 17: 3.17: Forecast of Dermatology (in USD Bn)
Exhibit 18: 3.18: Forecast of Gynaecology (in USD Bn)
Exhibit 19: 3.19: Forecast of Other Therapeutic Areas (in USD Bn)
Exhibit 20: 4.20: Forecast of Retail Pharmacy (Trade generics + Branded) (in USD Bn)
Exhibit 21: 4.21: Forecast of Branded Rx (in USD Bn)
Exhibit 22: 4.22: Forecast of Trade Generics / Unbranded (in USD Bn)
Exhibit 23: 4.23: Forecast of OTC / Self-medication (in USD Bn)
Exhibit 24: 4.24: Forecast of Hospital / Institutional (in USD Bn)
Exhibit 25: 4.25: Forecast of Private Hospital (in USD Bn)
Exhibit 26: 4.26: Forecast of Government (Ayushman Bharat/PMJAY) (in USD Bn)
Exhibit 27: 4.27: Forecast of ESI / CGHS (in USD Bn)
Exhibit 28: 4.28: Forecast of Jan Aushadhi (Generic public stores) (in USD Bn)
Exhibit 29: 4.29: Forecast of E-Pharmacy (1mg, Apollo, PharmEasy) (in USD Bn)
Exhibit 30: 4.30: Forecast of Diagnostics-linked dispensing (in USD Bn)
Exhibit 31: 4.31: Forecast of Veterinary (pharma segment) (in USD Bn)
Exhibit 32: 6.32: Forecast of India (in USD Bn)
Exhibit 33: 6.33: Forecast of West India (in USD Bn)
Exhibit 34: 6.34: Forecast of West India (in USD Bn)
Exhibit 35: 6.35: Forecast of North India (in USD Bn)
Exhibit 36: 6.36: Forecast of North India (in USD Bn)
Exhibit 37: 6.37: Forecast of South India (in USD Bn)
Exhibit 38: 6.38: Forecast of South India (in USD Bn)
Exhibit 39: 6.39: Forecast of East India (in USD Bn)
Exhibit 40: 6.40: Forecast of East India (in USD Bn)
Exhibit 41: 6.41: Forecast of Central India (in USD Bn)
Exhibit 42: 6.42: Forecast of Central India (in USD Bn)
Exhibit 43: 6.43: Forecast of Maharashtra (in USD Bn)
Exhibit 44: 6.44: Forecast of Gujarat (in USD Bn)
Exhibit 45: 6.45: Forecast of Goa (in USD Bn)
Exhibit 46: 6.46: Forecast of Delhi NCR (in USD Bn)
Exhibit 47: 6.47: Forecast of Uttar Pradesh (in USD Bn)
Exhibit 48: 6.48: Forecast of Punjab (in USD Bn)
Exhibit 49: 6.49: Forecast of Haryana (in USD Bn)
Exhibit 50: 6.50: Forecast of Rajasthan (in USD Bn)
Exhibit 51: 6.51: Forecast of Tamil Nadu (in USD Bn)
Exhibit 52: 6.52: Forecast of Karnataka (in USD Bn)
Exhibit 53: 6.53: Forecast of Telangana (in USD Bn)
Exhibit 54: 6.54: Forecast of Andhra Pradesh (in USD Bn)
Exhibit 55: 6.55: Forecast of Kerala (in USD Bn)
Exhibit 56: 6.56: Forecast of West Bengal (in USD Bn)
Exhibit 57: 6.57: Forecast of Odisha (in USD Bn)
Exhibit 58: 6.58: Forecast of Bihar (in USD Bn)
Exhibit 59: 6.59: Forecast of Jharkhand (in USD Bn)
Exhibit 60: 6.60: Forecast of Madhya Pradesh (in USD Bn)
Exhibit 61: 6.61: Forecast of Chhattisgarh (in USD Bn)
Exhibit 62: 6.62: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)

Companies Covered

Sun Pharmaceutical, Cipla, Alkem Laboratories, Mankind Pharma, Lupin, Torrent Pharma, Zydus Lifesciences, Dr. Reddy's Labs, Ipca Laboratories, Abbott India, Pfizer India, Ajanta Pharma, Aurobindo Pharma, Natco Pharma, Biocon, Piramal Pharma, Sanofi India

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Buying Frequently for your Organization?

Need Custom Market Research Solution?

Tabs

Single User License (PDF)

Site License (PDF)*

Enterprise License (PDF)*

Latest Market Research Reports

Global Animal Feed Peptide Market Strategic

Global Food Peptide Market Strategic Research

BRICS Snapshot: PESTLE, SWOT, Risk &

Malaysia Corporate Training and Strategic

Global Medical Devices Industry Strategic

Global Healthcare Industry Strategic Research

About Us

Infomation